Genome-wide association studies in pharmacogenomics (original) (raw)

• Meyer, U. A. Pharmacogenetics — five decades of therapeutic lessons from genetic diversity. Nature Rev. Genet. 5, 669–676 (2004).
  Article CAS Google Scholar
• Daly, A. K. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med. 1, 10 (2009).
  Article Google Scholar
• Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).
  Article CAS Google Scholar
• Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nature Genet. 41, 1100–1104 (2009).
  Article CAS Google Scholar
• Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genet. 41, 1105–1109 (2009).
  Article CAS Google Scholar
• Shuldiner, A. R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849–857 (2009).
  Article CAS Google Scholar
• Cooper, G. M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022–1027 (2008).
  Article CAS Google Scholar
• Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
  Article Google Scholar
• Teichert, M. et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18, 3758–3768 (2009).
  Article CAS Google Scholar
• Link, E. et al. SLCO1B1 variants and statin-induced myopathy — a genomewide study. N. Engl. J. Med. 359, 789–799 (2008).
  Article CAS Google Scholar
• Daly, A. K. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genet. 41, 816–819 (2009).
  Article CAS Google Scholar
• Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137 (2006).
  Article CAS Google Scholar
• Kweekel, D., Guchelaar, H. J. & Gelderblom, H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat. Rev. 34, 656–669 (2008).
  Article CAS Google Scholar
• Naisbitt, D. J. et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol. 111, 1393–1403 (2003).
  Article CAS Google Scholar
• Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727–732 (2002).
  Article CAS Google Scholar
• Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568–579 (2008).
  Article Google Scholar
• Seeringer, A. & Kirchheiner, J. Pharmacogenetics-guided dose modifications of antidepressants. Clin. Lab. Med. 28, 619–626 (2008).
  Article Google Scholar
• Kirchheiner, J. et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 104, 173–192 (2001).
  Article CAS Google Scholar
• Hulot, J. S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244–2247 (2006).
  Article CAS Google Scholar
• Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009).
  Article CAS Google Scholar
• Collet, J. P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309–317 (2009).
  Article CAS Google Scholar
• Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429–1436 (2009).
  Article CAS Google Scholar
• Hoskins, J. M., Carey, L. A. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Rev. Cancer 9, 576–586 (2009).
  Article CAS Google Scholar
• Roden, D. M. et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145, 749–757 (2006).
  Article Google Scholar
• Liu, C. et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14, 575–581 (2008).
  Article CAS Google Scholar
• Lavedan, C. et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 14, 804–819 (2009).
  Article CAS Google Scholar
• Caldwell, M. D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106–4112 (2008).
  Article CAS Google Scholar
• Zhang, J. E. et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19, 781–789 (2009).
  Article CAS Google Scholar
• Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261–266 (2009).
  Article CAS Google Scholar
• Thijssen, H. H., Flinois, J.-P. & Beaune, P. H. Cytochrome P450 2C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos. 28, 1284–1290 (2000).
  CAS PubMed Google Scholar
• de Morais, S. M. F. et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419–15422 (1994).
  CAS PubMed Google Scholar
• Iadonato, S. P. & Katze, M. G. Genomics: hepatitis C virus gets personal. Nature 461, 357–358 (2009).
  Article CAS Google Scholar
• Becquemont, L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10, 961–969 (2009).
  Article CAS Google Scholar
• Wilke, R. A. et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nature Rev. Drug Discov. 6, 904–916 (2007).
  Article CAS Google Scholar
• Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130–133 (2010).
  Article CAS Google Scholar
• Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609–1616 (2009).
  Article CAS Google Scholar
• Trevino, L. R. et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972–5978 (2009).
  Article CAS Google Scholar
• Donaldson, P. T. et al. Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. Hepatology 48 (Suppl. 1), 396–397 (2008).
  Google Scholar
• Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186–195 (2008).
  Article CAS Google Scholar
• Khan, A. A. et al. Bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol. 36, 478–490 (2009).
  Article Google Scholar
• Sarasquete, M. E. et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112, 2709–2712 (2008).
  Article CAS Google Scholar
• Totah, R. A. & Rettie, A. E. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341–52 (2005).
  Article CAS Google Scholar
• Fleming, I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol. Res. 49, 525–533 (2004).
  Article CAS Google Scholar
• Choi, M. et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc. Natl Acad. Sci. USA 106, 19096–19101 (2009).
  Article CAS Google Scholar
• Strausberg, R. L., Levy, S. & Rogers, Y. H. Emerging DNA sequencing technologies for human genomic medicine. Drug Discov. Today 13, 569–577 (2008).
  Article CAS Google Scholar
• Paulussen, A. D. et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. 82, 182–188 (2004).
  Article CAS Google Scholar
• McCarthy, M. I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Rev. Genet. 9, 356–369 (2008).
  Article CAS Google Scholar
• Byun, E. et al. Genome-wide pharmacogenomic analysis of the response to interferon β therapy in multiple sclerosis. Arch. Neurol. 65, 337–344 (2008).
  Article Google Scholar
• Turner, S. T. et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52, 359–365 (2008).
  Article CAS Google Scholar
• Mick, E., Neale, B., Middleton, F. A., McGough, J. J. & Faraone, S. V. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1412–1418 (2008).
  Article CAS Google Scholar
• Yang, J. J. et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393–403 (2009).
  Article CAS Google Scholar
• Ising, M. et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66, 966–975 (2009).
  Article CAS Google Scholar
• Garriock, H. A. et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67, 133–138 (2010).
  Article CAS Google Scholar
• Hartford, C. et al. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 21, 2128–2136 (2007).
  Article CAS Google Scholar
• Inada, T. et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the γ-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet. Genomics 18, 317–323 (2008).
  Article CAS Google Scholar
• Volpi, S. et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry 14, 1024–1031 (2009).
  Article CAS Google Scholar